PHILOGEN
Italian-Swiss biotech and biopharma group
Philogen innovates to advance the treatment of cancer and other serious diseases, developing a strong pipeline of clinical-stage products.
Asset Class:
Private Equities - Directs
Thematic Outcomes:
Healthcare that is preventive and healing
Spectrum of Capital:
Sustainable